KR20160098257A - 세포독성 펩티드 및 그의 접합체 - Google Patents

세포독성 펩티드 및 그의 접합체 Download PDF

Info

Publication number
KR20160098257A
KR20160098257A KR1020167015935A KR20167015935A KR20160098257A KR 20160098257 A KR20160098257 A KR 20160098257A KR 1020167015935 A KR1020167015935 A KR 1020167015935A KR 20167015935 A KR20167015935 A KR 20167015935A KR 20160098257 A KR20160098257 A KR 20160098257A
Authority
KR
South Korea
Prior art keywords
alkyl
independently selected
nhc
mmol
rti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167015935A
Other languages
English (en)
Korean (ko)
Inventor
베른하르드 가이어스탄거
얀 그뤼네발트
웨이지아 오우
테츠오 우노
용친 완
싱 왕
윤호 진
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160098257A publication Critical patent/KR20160098257A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A61K47/48438—
    • A61K47/48569—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020167015935A 2013-12-17 2014-12-17 세포독성 펩티드 및 그의 접합체 Ceased KR20160098257A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917293P 2013-12-17 2013-12-17
US61/917,293 2013-12-17
PCT/US2014/070800 WO2015095301A2 (en) 2013-12-17 2014-12-17 Cytotoxic peptides and conjugates thereof

Publications (1)

Publication Number Publication Date
KR20160098257A true KR20160098257A (ko) 2016-08-18

Family

ID=52463118

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015935A Ceased KR20160098257A (ko) 2013-12-17 2014-12-17 세포독성 펩티드 및 그의 접합체

Country Status (16)

Country Link
US (3) US9988420B2 (enExample)
EP (2) EP3082877B1 (enExample)
JP (2) JP6636925B2 (enExample)
KR (1) KR20160098257A (enExample)
CN (1) CN105899526A (enExample)
AU (1) AU2014364812B2 (enExample)
BR (1) BR112016012538A2 (enExample)
CA (1) CA2930614A1 (enExample)
EA (1) EA201691251A1 (enExample)
ES (1) ES2758506T3 (enExample)
IL (1) IL245558B (enExample)
MX (1) MX2016007865A (enExample)
PL (1) PL3082877T3 (enExample)
PT (1) PT3082877T (enExample)
SG (1) SG11201604877UA (enExample)
WO (1) WO2015095301A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124316A2 (en) * 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
AU2014373640B2 (en) 2013-12-27 2018-08-30 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
EA201691827A1 (ru) * 2014-03-12 2017-01-30 Новартис Аг Конкретные участки для модификации антител с целью получения иммуноконъюгатов
BR112016028835A2 (pt) * 2014-06-13 2017-10-24 Novartis Ag derivados de auristatina e conjugados dos mesmos
CA2960899C (en) 2014-09-17 2021-08-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
UY38265A (es) * 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
WO2020103891A1 (en) * 2018-11-23 2020-05-28 Wuxi Biologics (Shanghai) Co. Ltd. ortho-Phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate
CA3170633A1 (en) * 2020-03-09 2021-09-16 David Goeddel Efficient preparation of dolastatin and auristatin analogs through a common intermediate
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN116761819A (zh) * 2021-01-18 2023-09-15 味之素株式会社 化合物或其盐、以及由它们得到的抗体
EP4420682A1 (en) * 2021-10-12 2024-08-28 Chengdu Scimount Pharmatech Co., Ltd. Highly-stable targeted linker-drug conjugate
AU2023313117A1 (en) * 2022-07-27 2025-02-13 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024152000A1 (en) * 2023-01-13 2024-07-18 The Trustees Of The University Of Pennsylvania Disruptable linker compositions, switchable bispecific t cell nanoengager (switch-bite) compositions comprising the same, and methods of use thereof
AR132368A1 (es) 2023-04-18 2025-06-18 Astrazeneca Ab Conjugados que comprenden enlazadores escindibles

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
ATE215962T1 (de) 1991-08-09 2002-04-15 Teikoku Hormone Mfg Co Ltd Tetrapeptide derivat
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
EP1912677B1 (en) 2005-06-20 2013-10-02 Psma Development Company, L.L.C. PSMA antibody-drug conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN103379912B (zh) 2010-09-29 2016-03-16 西雅图基因公司 正羧烷基耳他汀及其应用
US9272052B2 (en) 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
EP2678037B1 (en) 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
WO2012123423A1 (de) 2011-03-16 2012-09-20 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
ES2690993T3 (es) 2011-05-27 2018-11-23 Ambrx, Inc. Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos
SA112330989B1 (ar) 2011-11-17 2015-07-07 فايزر انك ببتيدات سامة للخلايا ومواد اقتران جسم مضاد وعقار منها
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2855520B1 (en) * 2012-06-04 2018-09-26 Novartis AG Site-specific labeling methods and molecules produced thereby
WO2014124316A2 (en) * 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates

Also Published As

Publication number Publication date
AU2014364812A1 (en) 2016-07-07
MX2016007865A (es) 2017-01-11
IL245558B (en) 2020-01-30
WO2015095301A2 (en) 2015-06-25
JP6636925B2 (ja) 2020-01-29
US20180244717A1 (en) 2018-08-30
AU2014364812B2 (en) 2017-05-25
EP3082877A2 (en) 2016-10-26
EA201691251A1 (ru) 2016-11-30
CN105899526A (zh) 2016-08-24
US10392421B2 (en) 2019-08-27
PT3082877T (pt) 2019-12-03
US20190382441A1 (en) 2019-12-19
US10787480B2 (en) 2020-09-29
CA2930614A1 (en) 2015-06-25
JP2020023514A (ja) 2020-02-13
JP2017503777A (ja) 2017-02-02
IL245558A0 (en) 2016-06-30
US20160311853A1 (en) 2016-10-27
BR112016012538A2 (pt) 2017-09-26
ES2758506T3 (es) 2020-05-05
PL3082877T3 (pl) 2020-02-28
EP3753578A1 (en) 2020-12-23
US9988420B2 (en) 2018-06-05
SG11201604877UA (en) 2016-07-28
WO2015095301A3 (en) 2015-09-03
EP3082877B1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
JP6636925B2 (ja) 細胞障害性ペプチドおよびその抱合体
EP3154997B1 (en) Auristatin derivatives and conjugates thereof
JP6498773B2 (ja) ベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
JP2018502131A (ja) ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
JP2022533215A (ja) 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
TW201836645A (zh) 具有酵素可裂解基團的細胞毒性藥劑之前藥
EP3215519A1 (en) Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
JP2018528161A (ja) Ｋｓｐ阻害剤との部位特異的均一複合体
WO2017191579A1 (en) Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
KR20240067085A (ko) 항체 약물 접합체에 사용하기 위한 링커
KR102858995B1 (ko) 설포말레이미드계 링커 및 상응하는 컨쥬게이트
JP7023933B2 (ja) セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
KR20250133764A (ko) 링커, 약물 링커 및 그의 접합체 및 그의 사용 방법
TW202506691A (zh) Ｓｔｉｎｇ促效劑化合物及其結合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210324

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210615

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210324

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I